2025-12-25 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical Inc. (ISRG) based on the data you provided, broken down into sections as requested:

**1.  Return Rate Comparison:**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **ISRG Cumulative Return:** 111.57%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:**
    *   **Current:** 10.7
    *   **Relative Divergence:** 35.5 (Indicates that the current divergence is at the 35.5th percentile of the historical divergence range).

**Analysis of Alpha, Beta, CAGR, MDD Table:**

*   **CAGR (Compound Annual Growth Rate):** ISRG has exhibited strong historical CAGR, fluctuating significantly over different 3-year periods.  Notably high CAGRs are seen from 2015-2019, while more recent periods (2018-2023) show negative growth.
*   **MDD (Maximum Drawdown):** The MDD figures are consistently high, indicating substantial risk/volatility.  A high MDD means there were periods of significant price decline.
*   **Alpha:** Alpha is generally positive in earlier periods (2015-2019), suggesting outperformance relative to its benchmark. However, more recent periods (2018-2024) show negative Alpha, indicating underperformance. The Alpha improved significantly in the most recent period, however, at 15.0%.
*   **Beta:** Beta values are generally low, especially in the early periods (2015-2018), which suggests the stock was less sensitive to market movements. The Beta values increased over time, suggesting ISRG's sensitivity to market movements is growing.
*   **Cap(B) (Market Capitalization in Billions):** The market capitalization of Intuitive Surgical has grown considerably over the periods analyzed, reaching a substantial size and stabilizing around 200 billion USD.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 572.47
*   **Last Market Data:** Price: 577.15, Previous Close: 577.34, Change: -0.03
*   **5-day SMA:** 561.06
*   **20-day SMA:** 564.08
*   **60-day SMA:** 522.79

**Analysis:**
The current price is above all the moving averages, which is generally a bullish signal. However, the current price is below the most recent market price. The 5-day and 20-day SMAs are very close, suggesting a short-term consolidation. The significant difference between the 60-day SMA and the shorter-term SMAs suggests that the stock has had a significant upward move in the last 2 months.

**3. RSI, PPO, Divergence, and Expected Return Analysis:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 52.71 (Neutral)
*   **PPO:** -0.34 (Slightly below zero, indicating potential weakness)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20 days) relative divergence change:** 8.0 (+) (Short-term upward trend)
*   **Expected Return:** 23.9% (Expected excess return compared to S&P 500 if invested long-term)

**Analysis:**

*   The MRI suggests a medium level of investment is appropriate.
*   The RSI indicates a neutral condition, not overbought or oversold.
*   The PPO being slightly negative suggests some short-term weakness but is not significantly bearish.
*   The Hybrid Signal suggests a strong buy with no cash holding.
*   The relative divergence change confirms recent upward momentum.
*   The expected return is attractive, indicating the potential for long-term outperformance.
*   The minimal recent price change (-0.03) in the last market data suggests minimal fluctuation.

**4. Recent News & Significant Events:**

*   Several articles highlight positive sentiment towards Intuitive Surgical.
*   **Key Themes:**
    *   **FDA Approval:** One article mentions a key medical robotics name winning FDA approval. This is significant as it opens new markets and revenue streams for ISRG's products.
    *   **Wall Street Bullishness:** The articles highlight a positive outlook from Wall Street analysts, suggesting confidence in the company's future performance.
    *   **Institutional Investment:**  The news about Swedbank AB holding a significant amount of ISRG stock indicates confidence from institutional investors.
    *   **Stock Surge:** One article points out a significant surge in the stock price and explores the reasons behind it, suggesting positive market reaction to recent events.
    *   **Comparison to Competitors:** An article comparing ISRG to Stryker provides insights into the company's competitive position within the MedTech sector.

**Analysis:**
The news flow is overwhelmingly positive, with articles focusing on FDA approvals, analyst optimism, and institutional investment. This supports a bullish outlook for the stock.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 2.06 (~Buy)
*   **Number of Opinions:** 29
*   **Target Price (avg/high/low):** 599.60 / 700.00 / 378.00

**Analysis:**

*   The analyst consensus is strongly leaning towards a "Buy" rating, suggesting that analysts are generally optimistic about the stock's future performance.
*   The average target price is higher than the current price, indicating potential upside. The high target price suggests that some analysts have even higher expectations. The low target price acts as a warning, however, that some analysts may expect it to go lower.
*   There are no recent rating changes, indicating that the analysts' opinions haven't changed.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-10-22 | 1.98 | 2.51 B$     |
| 2025-07-23 | 1.84 | 2.44 B$     |
| 2025-04-23 | 1.95 | 2.25 B$     |
| 2024-10-18 | 1.59 | 2.04 B$     |
| 2025-10-22 | 1.59 | 2.04 B$     |

**Analysis:**

*   Overall, both EPS and Revenue are on an upward trend. This indicates that the company is growing its earnings and sales effectively.
*   The most recent quarter (2025-10-22) shows strong EPS and revenue figures, indicating positive momentum.

**6. Financial Information Analysis:**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $2.51B   | 66.36%        |
| 2025-06-30   | $2.44B   | 66.31%        |
| 2025-03-31   | $2.25B   | 64.69%        |
| 2024-12-31   | $2.41B   | 68.04%        |
| 2024-09-30   | $2.04B   | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE    |
|--------------|----------|--------|
| 2025-09-30   | $16.93B  | 4.16%  |
| 2025-06-30   | $17.85B  | 3.69%  |
| 2025-03-31   | $17.11B  | 4.08%  |
| 2024-12-31   | $16.43B  | 4.17%  |
| 2024-09-30   | $15.58B  | 3.63%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue is consistently increasing, indicating strong demand for ISRG's products and services. The profit margins remain high, suggesting that the company is efficiently managing its costs and maintaining pricing power.
*   **Capital and Profitability:** Equity is growing over time, showing the company's increasing net worth. ROE (Return on Equity) fluctuates slightly but remains relatively stable, indicating consistent profitability relative to equity.

**7. Comprehensive Analysis (Summary):**

Overall, the analysis suggests a **positive outlook** for Intuitive Surgical (ISRG).

*   **Financial Performance:** Strong revenue growth, high profit margins, and increasing equity indicate a healthy and growing company. The recent earnings data further supports this.
*   **Market Sentiment:** Positive news flow, bullish analyst ratings, and institutional investment suggest that the market has confidence in the company's future prospects.
*   **Technical Indicators:** While some indicators like the PPO show minor weakness, the overall technical picture (price above SMAs, positive divergence change) is constructive.
*   **Risk Factors:** The high MDD indicates volatility. Additionally, while the news flow is positive, investors should still conduct their own due diligence, as the markets may react differently.
*   **Investment Recommendation:** Based on this analysis, ISRG appears to be a worthwhile investment, but it's crucial to consider your risk tolerance and conduct further research. The Hybrid Signal also suggests a "Buy" signal and that there's no need for cash. The MRI indicates a medium level of investment. The high expected return suggests potential for long-term outperformance.

**Disclaimer:** This is an analysis based on the provided data and should not be considered financial advice. Please consult with a qualified financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.